Circulating Tumor Cells Market Size & Share 2023 to 2032
Market Size by Technology (CTC Detection & Enrichment, CTC Direct Detection), Application (Research, Clinical), Product (Devices or Systems, Kits & Assays).
Report ID: GMI6095
|
Published Date: June 2023
|
Report Format: PDF
Download Free PDF
Authors:
Mariam Faizullabhoy, Gauri Wani
Circulating Tumor Cells Market Size
Circulating Tumor Cells Market size accounted for USD 11.1 billion in 2022 and is estimated to grow at a CAGR of 12.1% to reach USD 33.5 billion by 2032. The rising incidence of cancer across the globe has led to an increased demand for effective diagnostic and treatment solutions.
Circulating Tumor Cells Market Key Takeaways
Market Size & Growth
Key Market Drivers
Challenges
CTCs hold immense potential for early cancer detection, monitoring treatment response, and predicting disease progression. Also, advancements in technology and the development of innovative CTC detection and isolation techniques have greatly enhanced the accuracy and reliability of CTC-based diagnostics. Furthermore, the growing focus on personalized medicine and targeted therapies has created a need for precise and real-time information about tumor characteristics, that can be obtained through CTC analysis. Therefore, the integration of CTC-based assays in clinical trials and the increasing adoption of liquid biopsy approaches in routine cancer care are further fuelling the market growth.
Circulating Tumor Cells (CTCs) are cancer cells that have detached from a solid tumor and entered the bloodstream or lymphatic system. These cells can travel through the circulatory system to distant parts of the body, potentially leading to the formation of secondary tumors, known as metastases, in other organs or tissues.
COVID-19 Impact
The COVID-19 pandemic had a significant impact on the circulating tumor cells market. The pandemic caused disruptions in healthcare systems worldwide, leading to delays in cancer screenings, diagnosis, and treatment. This, in turn, affected the demand for CTC-based tests and technologies. Moreover, restrictions on non-essential medical procedures and reduced patient visits to healthcare facilities resulted in a decline in the adoption of CTC-based assays.
Additionally, the financial constraints faced by healthcare institutions and the prioritization of resources towards COVID-19-related care further impacted the market. However, as the world gradually recovered from the pandemic, the CTC market is expected to regain momentum as the importance of early cancer detection and personalized treatment strategies becomes increasingly recognized.
Circulating Tumor Cells Market Trends
Increasing number of cancer cases globally will have a positive impact on the market value. For instance, as per the American Cancer Society, in 2022, the total number of new cancer cases were 1.9 million and 609,360 cancer deaths in the U.S. alone. As cancer prevalence rises, there is a growing need for effective cancer diagnostics and monitoring tools along with CTC-based assays and technologies. This presents a significant opportunity for companies operating in the market to develop innovative products and solutions that enable the detection, enumeration, and molecular characterization of CTCs. Additionally, the growing interest in liquid biopsy approaches further fuels the demand for CTC-based technologies, as they offer a non-invasive method for real-time monitoring of cancer patients.
Circulating Tumor Cells Market Restraint
Limited awareness and adoption of CTCs can hamper the market expansion. Due to various factors such as lack of awareness among healthcare professionals, limited availability of CTC-based tests, and high costs associated with their implementation, many healthcare providers and patients remain unaware of the benefits and potential applications of CTC technology. This lack of awareness and understanding has hindered the widespread adoption of CTC-based diagnostics and therapies, thereby hindering the growth and development of the market.
Circulating Tumor Cells Market Analysis
By technology, the circulating tumor cells market is classified into CTC detection and enrichment method, CTC direct detection methods, and CTC analysis. The CTC detection and enrichment method segment is further classified into immunocapture, size-based separation, density-based separation, and combined methods. The CTC detection and enrichment method segment held largest revenue share of 65.9% in 2022. The ability to detect and enrich CTCs from a patient's blood sample provides valuable insights into tumor heterogeneity, metastatic potential, and treatment resistance. These methods enable researchers and clinicians to analyse CTCs at cellular level, uncovering crucial information about tumor biology and aiding in the development of targeted therapies.
Moreover, CTCs offer a non-invasive alternative to traditional tissue biopsies, allowing regular monitoring of disease progression and enabling the early detection of tumor metastasis. With several ongoing advancements in CTC detection technologies along with aforementioned advantages, the segment is anticipated to witness high growth over the forecast period.
Based on application, the CTC market is segmented into research and clinical applications. The research segment is further divided into cancer stem cell & tumorogenesis research and drug/therapy development. The research segment occupied high revenue of USD 8.1 billion in 2022. Circulating tumor cells (CTCs) are widely used in cancer research, offering valuable insights into tumor biology and cancer prognosis. Moreover, CTCs can be used for monitoring the disease and detecting early signs of metastasis, allowing timely intervention and improved patient outcomes. Further, growing interest of researchers in CTCs and its several applications in cancer research is expected to augment the segment trends.
By product, the circulating tumor cells market is segmented into devices or systems, kits & assays, and consumables. The devices or systems segment held highest market share of 46% in 2022 and is anticipated to grow at a substantial rate over the analysis period. Significant surge in the adoption of devices or systems used in the isolation of circulating tumor cells (CTCs) can be attributed to the growing usage of CTCs for cancer diagnosis, prognosis, and treatment monitoring. These devices and systems offer higher sensitivity, specificity, and efficiency in capturing CTCs from peripheral blood samples. The ease of use, scalability, and compatibility of these devices have further fuelled their widespread adoption.
Based on specimen, the circulating tumor cells market is categorized into blood, bone marrow, and other body fluids. The blood segment held highest market share of 47.6% in 2022. Blood is the most widely used for detecting and analysing circulating tumor cells (CTCs). As CTCs are shed into the bloodstream by tumors, blood samples offer a non-invasive means to capture these cells, providing valuable insights into cancer progression and treatment response.
Moreover, blood is an ideal source for early detection and monitoring of metastasis. The relatively high concentration of CTCs in blood samples compared to other bodily fluids further enhances their detection, facilitating detailed genetic and molecular analysis to guide personalized treatment strategies. Therefore, high utilization of blood for studying CTCs is anticipated to promote high segment progression.
Based on end-use, the circulating tumor cells market is categorized into research and academic institutes, hospital and clinics, and diagnostic centers. The research and academic institute segment held considerable market share in 2022. Growing utilization of CTCs in research and academic institutes for cancer related research is enhancing the segment growth. Similarly, growing cases of cancer globally is surging the demand for research, thereby supplementing the segmental revenue.
North America circulating tumor cells market accounted for 42.4% business share in 2022 and is anticipated to grow at a considerable growth rate during the forecast timeframe. Increasing prevalence of cancer in the region coupled with advancements in diagnostic technologies as well as rising awareness among healthcare professionals has contributed to the flourishing CTCs market. Also, robust healthcare infrastructure, coupled with significant investments in research and development, has paved the way for innovative CTC detection and analysis techniques.
Moreover, the region's strong emphasis on precision medicine and targeted therapies has further accelerated the demand for CTC-based diagnostics and monitoring tools. Further, with a growing number of pharmaceutical companies and biotechnology firms actively engaged in CTC research, North America continues to be a key hub for advancements in this field, thereby driving the regional market demand.
Circulating Tumor Cells Market Share
Major market players operating in the circulating tumor cells market include
These industry players majorly adopt various strategies including collaborations, acquisitions, mergers, and partnerships to create a global footprint and sustain market competition.
Circulating Tumor Cells Industry News:
The circulating tumor cells market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments:
Click here to Buy Section of this Report
By Technology
By Application
By Product
By Specimen
By End-use
The above information is provided for the following regions and countries:
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Security & defense sector journals and trade press
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 30+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →